Pharmacological management of migraine

Migraine is the most common severe form of primary headache with a global prevalence of around one in seven people. It is the most common underlying headache disorder in patients with medication overuse headache.

Current status

This guideline was published in 2018 and updated most recently in 2026. It will be considered for review in three years. The review history and any updates to the guideline in the interim period are noted in the update report.

Who it's for

The clinical guideline will be of interest to healthcare professionals in primary and secondary care, including:

• general practitioners
• headache nurses
• neurologists
• pharmacists, and
• patients with migraine.

We have also produced a plain language booklet for patients, families and carers that covers:

• what migraines are
• the impact of migraines on daily life
• what treatments are available
• complications associated with migraines, and
• where people can get more information and support.

How this guideline was developed

This guideline was developed using a standard methodology based on a systematic review of the evidence. Further details can be found in SIGN 50: A Guideline Developer’s Handbook.

​ Current < 3 years